Amgen’s Repatha Passes CVOT Test, But Contribution To 2017 Sales Growth Unclear

Amgen’s PCSK9 inhibitor Repatha succeeded in the FOURIER cardiovascular outcomes study, but the data may not impact the company’s revenue until 2018 – after a potential revenue decline in 2017.

Amgen Inc. delivered a mixed bag of news to investors on Feb. 2, first revealing that the cholesterol-lowering therapy Repatha (evolocumab) passed its much-anticipated cardiovascular outcomes test, then reporting 2017 financial guidance that suggests the company will continue to see slow uptake for the PCSK9 inhibitor while sales for key products slump in the face of competition.

[Sidebar#PS119650]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip